CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

GLP-1 drugs are also engineered peptides ... The most advanced Maze program is MZE829, a small molecule designed to inhibit apolipoprotein L1, or APOL1. This protein is associated with a higher ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The GLP-1 market landscape for research and development ... Chen told the conference that WuXi Apptec plans to continue expanding small molecule Phase III and commercial pipeline capabilities ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Phase 2 stage CT-388, a dual GLP-1/GIP receptor agonist injected subcutaneously, CT-996, a Phase 1 stage oral, small molecule GLP-1 receptor agonist, and CT-868, a Phase-2, once-daily subcutaneous ...

ASC30 oral tablet demonstrated superior PK properties (including a longer t1/2 and higher AUC) to other small molecule oral GLP-1 receptor (GLP-1R) agonists in development, suggesting ASC30 oral ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may result ... long-acting peptides and oral small molecule agonists we are developing ...